Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia

Journal of Clinical Oncology

Volumn 19, Issue 8, 2001, Pages 2134-2141

  Witherspoon, R P ^a   Deeg, H J ^a   Storer, B ^a   Anasetti, C ^a   Storb, R ^a   Appelbaum, F R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MORTALITY; MYELODYSPLASIA; PRIORITY JOURNAL; REFRACTORY ANEMIA; STEADY STATE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035870828     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.8.2134     Document Type: Article

References (35)

1. Treatment of therapy-related leukemia and myelodysplastic syndrome
2. Prognosis and therapy of secondary myelodysplastic syndromes
3. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF)
4. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
5. Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy
6. Bone marrow transplantation for therapy-related myelodysplasia: Comparison with primary myelodysplasia
7. A patient-oriented approach to treatment of myelodysplastic syndromes
8. Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation
9. Allogeneic marrow transplantation for acute leukemia in relapse
10. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors
11. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide
12. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
13. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation
14. Phase II study of busulfan (BU) and total body irradiation (TBI) as a novel preparative regimen in allogenic marrow transplantation (BMT) for advanced myelodysplastic syndrome
15. High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma
16. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: A phase I study
17. Relapse after allogeneic bone marrow transplantation (BMT) for myelodysplasia (MDS) subtype refractory anemia (RA) is increased by shielding lungs and liver during irradiation
18. Aplastic anemia treated by allogeneic bone marrow transplantation: A report on 49 new cases from Seattle
19. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens
20. Bone-marrow transplantation
21. Cyclosporine as prophylaxis for graft-versus-host disease: A randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia
22. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study
23. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
24. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial
25. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: Randomized study comparing corticosteroids and cyclosporine
26. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroids
27. Nonparametric estimation from incomplete observations
28. Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors
29. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
30. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
31. International scoring system for evaluating prognosis in myelodysplastic syndromes
32. 131I-Anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
33. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation
34. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
35. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies